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Dexmedetomidine is a potent alpha-2-adrenergic agonist, 
more selective than clonidine, with widespread actions that 
include anxiolysis, sedation, anesthetic-sparing, analgesia and 
sympatholytic properties. Since its release in the US market 
in late 1999, it has gained remarkable attention in the adult, 
pediatric and geriatric populations, predominantly because 
of its minimal respiratory depression. A large body of recent 
work supports its favorable profile in many other clinical 
scenarios, including neuroprotection, cardioprotection and 
renoprotection, with promising results [1].
Even though dexmedetomidine displays various favorable 
pharmacological actions, it is believed that its routine use on 
patients undergoing surgery is not the current trend. The reason 
for this can be summed up in two ways. First, intraoperative 
hemodynamic unstability including hypotension and/or 
bradycardia due to sympatholysis may be problematic in some 
patients. Such hemodynamic effects of dexmedetomidine may 
be expected to be more pronounced in hypovolemic patients 
and in those with diabetes mellitus or chronic hypertension 
and in the elderly. Secondly, a delay in postanesthetic recovery 
is expected due to dexmedetomine’s relatively long duration of 
action compared to other short-acting anesthetics. This disad-
vantage means that dexmedetomidine is not suitable for day 
surgery patients.
An interesting study has been carried out associated with the 
effects of dexmedetomidine on intraoperative hemodynamics 
and postoperative recovery in this issue of Korean Journal 
of Anesthesiology [2]. Kang et al. [2] found that the changes 
in mean arterial pressure (MAP) during the operation in 
the dexmedetomidine group were significantly less than 
those in the control group, which means that intraoperative 
administration of dexmedetomidine produced more stable 
hemodynamics than in the control. In addition, the authors 
claimed that dexmedetomidine was not associated with 
prolongation of extubation time or compromised recovery 
profile. Although their study was small-scaled, with only 10 
patients involved in each group, their results are interesting 
in that they presented some evidence to dispel our concerns 
about dexmedetomidine-induced intraoperative hypotension 
and delay in postanesthetic recovery. These concerns have 
made us reluctant to the routine use of dexmedetomidine in the 
operating room.
The hemodynamic effects of dexmedetomidine are some-
what controversial. Hypotension and/or bradycardia are not 
unusual, because dexmedetomidine decreases sympathetic 
nervous system activity. On the other hand, transient 
hypertension has been observed primarily during the loading 
dose in association with the initial peripheral vasoconstrictive 
effects, although treatment of transient hypertension has 
generally not been necessary. Investigations in both humans 
and animals have revealed significant cerebral vasoconstrictive 
effects of dexmedetomidine [3,4]. Also, dexmedetomidine is 
known to be associated with higher MAP than midazolam in 
patients under epidural anesthesia [5]. Such controversies 
regarding hemodynamic effect are thought to be caused by 
biphasic action of dexmedetomidine, characterized by an 
initial short-term increase in MAP followed by a longer lasting 
hypotension. The biphasic action of dexmedetomidine is 
sometimes displayed in a dose-dependent manner, i.e., lower 
dosages reduce norepinephrine release, resulting in decrease 
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in vascular tone and hypotension, and higher dosages produce 
alpha-2B-mediated vasoconstriction and hypertension [6]. One 
factor that should be remembered is that the hemodynamic 
effect of dexmedetomidine during anesthesia is, to some 
extent, implicated with its anesthetic sparing effect, because 
dexmedetomidine reduces the required amount of anesthetics 
necessary to maintain adequate depth of anesthesia.
Dexmedetomidine is basically a central nervous system 
depressant with a relatively long duration of action, and thus it 
causes delayed postanesthetic recovery. As was revealed in the 
Bührer et al. [7], dexmedetomidine reduced the thiopental dose 
requirement for electroencephalographic burst suppression 
by 30%, which was not the result of a pharmaco  dynamic 
interaction but rather of a dexmedetomidine-induced decrease 
in thiopental distribution volume and distribution clearances. 
Also, dexmedetomidine decreases the BIS value itself [8]. These 
characteristics are considered to be responsible for delayed 
recovery from anesthesia after dexmedetomidine. On the other 
hand, some investigators reported that dexme  detomidine 
promoted an earlier emergence and reduced the length of stay 
in the postanesthetic care unit [9,10]. In these reports, they 
ascribed shorter recovery time to less amount of anesthetics 
needed when dexmedetomidine was co-admini  stered.
On the whole, the Kang et al. [2] results of the stable intra-
operative hemodynamics and the acceptable postanesthetic 
recovery speed in the dexmedetomidine group are thought to be 
related to the anesthetics-sparing effect of dexmedeto  midine, 
not solely to the pharmacologic effect of dexmedetomidine 
itself. In their study, the Ce (effecter-site concentration) of TCI-
propofol was controlled to the minimum dosage needed to 
maintain BIS of 45-55, while the Cp (plasma concentration) 
of TCI-remifentanil was fixed to be 10 ng/ml during the 
operation. They found that the mean infusion rate of propofol 
as supplement anesthetics was about 30% lower by co-
administration of dexmedetomidene than in the control. At 
the end of surgery, the Ce of propofol in the dexmedetomidine 
group was relatively lower than that in the control group. 
As a result, less propofol administration was responsible 
for less propofol-induced vasodilatory effect, which in turn 
maintained relatively stable intraoperative MAP, offsetting 
dexmedetomidine-induced delayed recovery.
Again, it should be reemphasized that the favorable hemo-
dynamics during anesthesia and the comparable speed of 
recovery after anesthesia is attributed to dexmedetomidine’s 
anesthetics sparing effect. Nevertheless, for the anesthetic 
management, dexmedetomidine-induced anesthetics sparing 
is meaningful in that a fundamental concept of anesthetic 
management is to minimize the side effects of anesthetic drugs 
by administrating the lowest dose necessary to maintain an 
adequate depth of anesthesia while ensuring a rapid recovery.
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